Irritable Bowel Syndrome Treatment Market, By Type (Irritable Bowel Syndrome with Constipation, Irritable Bowel Syndrome with Diarrhea, and Mixed Irritable Bowel Syndrome), By Indication (Abdominal Pain, Bloating, Constipation and Diarrhea, Altered Bowel

The Global Irritable Bowel Syndrome Treatment Market is estimated to be valued at USD 4.04 Bn in 2025 and is expected to reach USD 7.43 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032. Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder that affects the large intestine. IBS causes abdominal cramping, bloating, gas, and diarrhea and/or constipation. As per National Library of Medicine estimates, in June 2024, IBS affects around 11% of people worldwide. The exact causes of IBS are unknown, but it is believed to be due to changes in the way the gastrointestinal tract handles stress and regulates normal function and sensations. The global irritable bowel syndrome treatment market has been witnessing steady growth over the past few years owing to the increasing prevalence of IBS and growing demand for effective treatment options.

Market Dynamics:

The global irritable bowel syndrome treatment market is driven by the rising geriatric population, as seniors are more prone to develop IBS. According to the United Nations, the number of people aged 60 or above will increase from 962 million globally in 2017 to 2.1 billion in 2050. Moreover, growing awareness and better diagnosis of IBS are also supporting the growth of this market. However, the lack of approved drugs for IBS, high development costs of new therapies, and side effects associated with existing drugs are some of the key factors are hampering the market growth. The development of novel drug formulations and non-drug treatment alternatives can present lucrative opportunities in the market.

Key Features of the Study:

• This report provides in-depth analysis of the global irritable bowel syndrome treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global irritable bowel syndrome treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Ironwood Pharmaceuticals, Inc., AbbVie Inc., Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca Plc., Sebela Pharmaceuticals, Inc., Bausch Health Companies Inc., Theriva Biologics, Inc., Ardelyx, Inc., Salix Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Abbott Laboratories, Lexicon Pharmaceuticals, Inc., GSK plc, and Johnson & Johnson Services, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global irritable bowel syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

• By Type Insights (Revenue, USD Bn, 2020 - 2032)
• Irritable Bowel Syndrome with Constipation (IBS-C)
• Irritable Bowel Syndrome with Diarrhea (IBS-D)
• Mixed Irritable Bowel Syndrome (IBS-M)
• By Indication Insights (Revenue, USD Bn, 2020 - 2032)
• Abdominal Pain
• Bloating
• Constipation and Diarrhea
• Altered Bowel Habits
• Others
• By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
• Antispasmodics
• Laxatives
• Antidiarrheal Medications
• 5-HT3 Receptor Antagonists
• Guanylate Cyclase-C Agonists
• Anticholinergic
• Probiotics
• Antidepressants
• Antibiotics
• Dietary Supplements
• Others
• By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• Oral
• Rectal
• Parenteral
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Ironwood Pharmaceuticals, Inc.
• AbbVie Inc.
• Astellas Pharma, Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca Plc.
• Sebela Pharmaceuticals, Inc.
• Bausch Health Companies Inc.
• Theriva Biologics, Inc.
• Ardelyx, Inc.
• Salix Pharmaceuticals, Inc.
• Mallinckrodt Pharmaceuticals
• Abbott Laboratories
• Lexicon Pharmaceuticals, Inc.
• GSK plc
• Johnson & Johnson Services, Inc.